Citadel Advisors
EBAC

Citadel Advisors’s European Biotech Acquisition Corp. Class A Ordinary Shares EBAC Stock Holding History

Citadel Advisors’s Portfolio EBAC Stock Details EBAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-625,916
Closed -$6.1M – 14654
2022
Q1 		$6.1M Buy
625,916
+28
+0% +$272 ﹤0.01% 3800
2021
Q4 		$6.07M Buy
625,888
+141
+0% +$1.37K ﹤0.01% 3961
2021
Q3 		$6.05M Buy
625,747
+469
+0.1% +$4.54K ﹤0.01% 3944
2021
Q2 		$6.04M Buy
+625,278
New +$6.14M ﹤0.01% 4052

Other funds holding EBAC

GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
PMAM
Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 50.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Citadel Advisors's EBAC Position: Q2 2022 in Review

Citadel Advisors sold out of European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) in Q2 2022, closing a stake of 625,916 shares — an estimated $6.1M sold.

Citadel Advisors first reported a position in EBAC in Q2 2021 and held it in 4 quarters. The position peaked at $6.1M in Q1 2022. 46 funds tracked by Wall St. Rank hold EBAC as of Q2 2022.

  • Citadel Advisors reported no remaining European Biotech Acquisition Corp. Class A Ordinary Shares position as of Q2 2022 after selling out during the quarter.
  • Citadel Advisors sold 625,916 European Biotech Acquisition Corp. Class A Ordinary Shares shares in Q2 2022, an estimated $6.1M.
  • Citadel Advisors first reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares in Q2 2021 and held it in 4 quarters.
  • Citadel Advisors's European Biotech Acquisition Corp. Class A Ordinary Shares position peaked at $6.1M in Q1 2022.
  • 46 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Class A Ordinary Shares as of Q2 2022.

Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.